Payment overview · 2025
General Payments
$119.86
6 reported records · 5 companies
Healthcare provider profile · identity verified
Charles Erickson Probst, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LAUREL, MS · NPI 1477864585
Verified facts
What the public records show
CMS Open Payments records show Charles Erickson Probst, D.O. received $119.86 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.74 | 34.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.79 | 20.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.69 | 18.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.21 | 15.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.43 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $119.86 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 59 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 439 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 280 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 85 |
| Gabapentin | Gabapentin | 245 | 86 |
| Losartan Potassium | Losartan Potassium | 240 | 74 |
| Meloxicam | Meloxicam | 206 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 53 |
| Trazodone Hcl | Trazodone Hcl | 172 | 57 |
| Potassium Chloride | Potassium Chloride | 167 | 52 |
| Metformin Hcl | Metformin Hcl | 149 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 50 |
| Furosemide | Furosemide | 139 | 45 |
| Omeprazole | Omeprazole | 132 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 96 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 35 |
| Lisinopril | Lisinopril | 101 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 33 |
| Metformin Hcl Er | Metformin Hcl | 87 | 24 |
| Sertraline Hcl | Sertraline Hcl | 84 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 33 |
| Glimepiride | Glimepiride | 77 | 23 |
| Prednisone | Prednisone | 77 | 70 |
| Pregabalin | Pregabalin | 76 | 19 |
| Carvedilol | Carvedilol | 73 | 23 |
| Ozempic | Semaglutide | 73 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 33 |
| Montelukast Sodium | Montelukast Sodium | 70 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 16 |
| Mounjaro | Tirzepatide | 62 | 12 |
| Eliquis | Apixaban | 59 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 17 |
| Clonidine Hcl | Clonidine Hcl | 55 | 16 |
| Allopurinol | Allopurinol | 52 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 30 |
| Baclofen | Baclofen | 49 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 17 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 18 |
| Linzess | Linaclotide | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 13 |
| Irbesartan | Irbesartan | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 14 |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Meclizine Hcl | Meclizine Hcl | 31 | 18 |
| Fluconazole | Fluconazole | 30 | 18 |
| Bupropion Xl | Bupropion Hcl | 29 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Finasteride | Finasteride | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Glipizide | Glipizide | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | 11 |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $119.86 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ELIQUIS, FARXIGA, NURTEC ODT, Ozempic, SHINGRIX, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error